Pazopanib
Overview
Pazopanib is a potent multi-targeted receptor tyrosine kinase inhibitor that inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α/β, and c-Kit. It is used in the treatment of renal cell carcinoma and soft tissue sarcoma.
API suppliers (2)
Suppliers of Pazopanib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
2 of 2 hold a GMP certificate on record in the EU or UK registers
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- CDYMAX (INDIA) PHARMA PRIVATE LIMITEDIndia1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (7 approved US products), the latest listed US patent on Pazopanib expires — and exclusivity 6 May 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Pazopanib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.